Blog

SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Monday, June 16th, at 2:30pm at the BIO International Convention 2025 in Boston, MA.

Event Information:

Event	NanoViricides Presentation at the BIO International Convention, 2025, Boston, MA
Day & Date	Monday, June 16, 2025
Time	2:30 pm
Location	Room 153B, Boston Convention and Exhibition Center

Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.

Dr. Diwan will also be available for meetings in the BIO Partnering™ match-making platform during the Convention from June 16th through June 19th, 2025.

NanoViricides’ Current Antiviral Drugs Pipeline

NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region.

NV-387 is a revolutionary broad-spectrum drug candidate designed to mimic host-side features that the virus particle uses as the first landing site in order to mount a cellular infection. An estimated 90-95% of human pathogens utilize the same common landing feature that is mimicked by NV-387, giving the drug its extremely broad antiviral spectrum.

NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs.

The virus cannot escape NV-387 even as it changes in the field, because the virus continues to use the sulfated proteoglycan features for attachment despite all changes. This is completely unlike existing vaccines, antibodies, and small chemical anti-viral modalities that are all readily defeated by viruses by relatively small changes, often in single viral proteins.

The overall market size of NV-387 indications is estimated to be well in excess of $10 billion.

NV-387 is expected to become an “emperic therapy” for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections.

NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection.

In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.

The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.

NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code-Specific Delivery

Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.

Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.

Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.

ABOUT BIO INTERNATIONAL CONVENTION

The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

In a time of remarkable discovery and progress, the biotechnology industry stands at the forefront of a revolution changing how we live, heal, and care. From pioneering treatments offering hope to millions, to sustainable agricultural innovations to feed a growing population, or environmental breakthroughs securing our future, biotech drives positive change faster than ever. This progress is not just a change but a promise for a brighter future. The world is ready.

Whether you work at a public pharmaceutical company, biotech startup, academia, non-profit organization, or government agency; or you work as a researcher, business development professional or investor, BIO is where you’ll make valuable connections and build relationships. Our proprietary BIO Partnering™ match-making platform-exclusive to the Premier Access registration package-allows you to find potential partners, schedule and accept meetings.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

SOURCE: NanoViricides, Inc.

View the original press release on ACCESS Newswire

NORTH PALM BEACH, FL / ACCESS Newswire / May 27, 2025 / The world of offshore sport fishing is a very close-knit community, and there are very few names that stir the sea quite like Taylor Jean. This Viking Convertible, which is 62 feet in length, is a unique and exceptional tournament yacht. It is sleek and powerful, and it is helmed by a crew that lives and breathes the wide sea. It is a story that is unfolding. From the 28th through the 31st of May 2025, it will once again be the center of attention at the 2nd Annual Walker’s Cay Blue Marlin Open, which is widely considered to be one of the most anticipated fishing competitions in the Bahamas.

A Yacht Built for Glory

Whenever Taylor Jean arrives at a marina, it is difficult to avoid staring at her. It is a beast that was built for speed and precision, as evidenced by its sleek lines, towering outriggers, and twin MTU motors that produce 2002 horsepower each. On the other hand, once you climb onboard, you will experience something else: a sense of purpose. Rather than being only a machine for sport fishing, this vessel serves as a floating home for a group of people who have become like family.

The current Taylor Jean, which first embarked in 2022, was designed with a single objective in mind, to strive for greatness. It is capable of performing with elegance and efficiency, whether it is traveling through the waters of the Bahamas at a speed of 36 knots or managing a hot bite on the tournament circuit.

The Crew Behind the Legend

What truly sets Taylor Jean apart isn’t just its speed, its engineering, or its tournament record, it’s the heartbeat of the boat, the people on board. Behind the polished teak, cutting-edge electronics, and twin MTU engines is a crew bound not just by a love for the ocean but by a shared spirit of competition, trust, and grit. Every line cast, every fish fought, every mile cruised, and it’s the crew that brings it to life.

Blaine Birch, a former collegiate lacrosse player with an unmistakable competitive edge, is currently serving as the captain of the crew. In every excursion, Blaine brings his keen instincts and his ability to lead with composure, guiding his group with self-assurance and a sense of togetherness.

Ken Hager, the owner, is also present, and he is not only the one who finances the dream. He is a living example. This crew is more than just a squad because it includes long-time teammates such as Dave McKendrick and Jarrett Birch (yep, Blaine’s brother). There’s a rhythm to this crew, one built on years of early mornings, high-stakes moments, and the kind of trust you can only earn at sea. They’ve celebrated wins, pushed through quiet days, and built a friendship that runs deeper than most tides. And tucked into their routine is a little superstition that’s become a legend among those who know them, before every tournament, someone scatters a handful of Lucky Charms into the water. No speeches. No ceremony. Just a quiet nod to tradition, a ritual that feels half superstition, half inside joke, and all heart. Maybe it’s luck. Perhaps it’s just who they are. Either way, it’s worked pretty well so far.

A Track Record That Speaks for Itself

Taylor Jean has been in the winner’s circle for quite some time. They finished in third place at the White Marlin Open in 2023, earning a total of 665 points. This is an impressive accomplishment in an event where the competition is just as fierce as the fish themselves. They then followed that up with an equally impressive performance in 2024, which resulted in them matching for third place in the Billfish release division with 770 points.

The yacht has also built a curious streak-claiming top finishes at The MidAtlantic every odd-numbered year since 2017. That kind of consistency speaks to more than just skill. It speaks to tenacity, preparation, and a team that knows how to rise when the stakes are highest.

What’s Coming: The 2025 Walker’s Cay Blue Marlin Open

Now, all eyes are on Walker’s Cay, which has been meticulously renovated and redesigned to become a crown jewel in the Bahamas. In addition to being famous for its deep-water drop-offs and legendary fishing, Walker’s is the ideal location for a Sportfishing Tournament that combines the excitement of competition with the sophistication of the past.

This is not your typical dockside competition, the Walker’s Cay SFC Blue Marlin Open is unlike any other. This event celebrates sport as much as it honors tradition, featuring a full sit-down Captain’s Dinner, an air-conditioned Awards Banquet, and spectacular ocean views.

Taylor Jean’s staff is already getting ready for the event, which includes adjusting the equipment, reviewing the charts, watching films from previous events, and, of course, making sure that the cereal boxes are stocked.

From High Stakes to High Seas: Charter Services with Taylor Jean

However, Taylor Jean is not only a dominant force in tournaments. In addition to that, it provides memorable charter fishing experiences for anyone interested in experiencing life at sea. It doesn’t matter if you’re looking for a day trip to go tuna fishing, a weekend vacation to go sailfish fishing, or just a chance to unplug with your loved ones and friends in opulent surroundings, the Taylor Jean experience will not disappoint.

By putting themselves in the same shoes that champion anglers have worn, guests are accompanied by seasoned anglers, supplied with the best equipment available, and cruise onboard one of the most luxurious yachts in its category. Every charter is customized to the guest’s level of experience if you are a dedicated offshore junkie or a first-timer to the underwater world.

The Legacy Continues

So, what is it about Taylor Jean that sets her apart? It may be the connection that exists between the members of the crew. It is the unwavering concentration. There is a possibility that it is the ideal combination of meticulous engineering and unbridled determination. It could be all of that and much more than that.

There is one thing that can be said with absolute certainty: on May 28th, Taylor Jean will once again be in its element, slashing through the blue of the Bahamas and running after another opportunity to make history.

Are they going to be successful in securing the big one at Walker’s Cay this year? If previous competitions are any indication, keep a close eye on this boat and consider bringing a box of Lucky Charms with you.

To reserve your own adventure, visit https://www.taylorjeanfishing.com/

To follow along on the road to Walker’s Cay, check out their Instagram: @taylorjean_sportfishing and @seabirdsac.

You can also catch full coverage and updates on the tournament at sportfishingchampionship.com, as well as through media like the Miami Herald, which regularly spotlights standout moments from the world of competitive sportfishing.

City, State: North Palm Beach, Florida
Name: Kenneth Hager
Company Name: Taylor Jean FL, LLC
Email Address: ken@taylorjeanfishing.com
Contact Number: (908) 433-6487
Website: taylorjeanfishing.com

SOURCE: Taylor Jean FL, LLC

View the original press release on ACCESS Newswire

Founded by trading educator Jordan Fogel, the platform offers AI-powered options strategies with built-in risk management and hands-off execution

MIAMI, FL / ACCESS Newswire / May 27, 2025 / Cashflow AI (https://trycashflowai.com), a financial technology company specializing in automated options trading, has officially launched its hands-free platform designed to help investors generate consistent passive income through artificial intelligence. The platform provides a modern, accessible solution for capital growth through fully autonomous trading logic-without requiring users to manually execute trades or understand technical charts.

Built for professionals, retirees, and high-net-worth individuals, Cashflow AI connects directly to a user’s U.S.-regulated brokerage account and executes trades based on proven, logic-driven strategies. The platform is compatible with trusted brokers such as Tradier, Charles Schwab, and TastyTrade, allowing users to maintain full control of their capital in their own accounts while the automation operates securely in the background.

The company was founded by veteran trader Jordan Fogel, who previously built Freedom Team Trading, a successful trading education company that supported over 1,000 students and helped generate millions in reported profits. After years of working with individual traders, Fogel saw the need for a simpler, scalable way to participate in the markets-one that eliminates emotional decision-making, missed entries, and over complication.

“Cashflow AI is designed for people who want their money working for them without micromanaging trades,” said a company representative. “We’re focused on stability, transparency, and long-term performance-not hype or speculation.”

How it works:

1. Connect a U.S.-regulated brokerage account

2. Activate the Cashflow AI trading bot

3. Monitor trades and income via a real-time dashboard

All trading is handled automatically using proprietary logic developed by a team with experience in over $500 million of trading volume. The platform’s AI Guardrail™ halts trades during periods of unusual volatility, and the AutoHedge™ system enters both bullish and bearish positions to reduce risk and improve consistency in range-bound or uncertain markets.

Unlike many competitors offering Forex bots or crypto-based systems, Cashflow AI does not use martingale strategies or high-risk compounding models that can jeopardize account balances during drawdowns. Every strategy is rules-based, transparent, and backed by real-world testing in regulated U.S. markets.

Case Study: 15.1% Gain During 2025 Market Crash

Earlier this year, Cashflow AI put its system to the test by deploying a new $50,000 account during what many investors referred to as a market crash. Over the span of 90 days-amid high volatility, uncertainty, and sharp market drops-the account returned a 15.1% gain, fully automated and without any manual trades. The results were documented publicly on the company’s YouTube channel to demonstrate the platform’s real-time decision-making, resilience, and hands-free execution.

This performance was made possible by Cashflow AI’s core risk management features, including its AI Guardrail™ and AutoHedge™ logic. The results highlight how the system adapts to market conditions intelligently-protecting capital while continuing to seek profit opportunities.

With rising demand for passive income and smart investing, Cashflow AI offers a robust alternative to traditional trading or speculative platforms. Its focus on safety, autonomy, and real-world performance makes it an attractive option for those looking to generate income with confidence.

To learn more, visit https://trycashflowai.com.

---

Media Contact:
Cashflow AI LLC
Email: jordan@getcashflowai.com
Website: https://trycashflowai.com

SOURCE: Cashflow AI

View the original press release on ACCESS Newswire

With tech visionaries like Chris Urmson, Clay Bavor, and Dorothy Kilroy, Elevate 2025 promises bold ideas, startup deal flow, and a look at what’s next.

TORONTO, ON / ACCESS Newswire / May 27, 2025 / Canada’s largest made-in-Canada tech and innovation event, Elevate Festival, returns October 7-9 for its seventh annual event at downtown Toronto’s Meridian Hall and St. Lawrence Centre. Organized by Elevate, the non-profit organization that acquired CIX Summit in 2024, Elevate Festival expects 10,000 attendees from across the global tech community, featuring over 250 speakers across eight specialized content tracks.

The festival continues to lead the industry in gender diversity, with 51% of attendees identifying as women or non-binary – significantly exceeding typical tech event benchmarks. Last year’s Elevate Festival catalyzed hundreds of thousands of dollars in direct startup investments, with this year’s event positioned to deliver a similar economic impact for Canada’s innovation ecosystem.

World-Class AI Leaders Takes Center Stage
Following an extraordinary legacy of transformative speakers including former First Lady Michelle Obama, former Google CEO Eric Schmidt, and award-winning tech journalist Kara Swisher, the 2025 lineup delivers world-class inspiration with applied AI as the defining theme. As the industry reflects on lessons learned from AI’s unprecedented acceleration over the past 18 months, this year’s speakers offer critical insights on navigating the next phase of tech transformation responsibly. Featured speakers include:

• Clay Bavor, Co-Founder of Sierra: He co-founded Sierra with former Salesforce co-CEO Bret Taylor to revolutionize customer experience through AI agents, and raised $285 million to serve major brands like WeightWatchers and SiriusXM.

• Chris Urmson, Co-Founder and CEO of Aurora: A Canadian pioneer in self-driving tech. He led Google’s autonomous vehicle project and now oversees driverless freight operations in Texas with Aurora, pushing the boundaries of commercial autonomous trucking.

• Dorothy Kilroy, Chief Commercial Officer at OURAHealth: Former Airbnb executive who led 4M+ hosts globally, creating $180B in earnings. At OURA, she drives partnerships for the $2.55 billion wearables company with major brands including Best Buy, Gucci, and Strava.

• Erika Ayers Badan, CEO of Food52 and former CEO of Barstool Sports: She grew Barstool Sports valuation from $15 million to $450 million. She’s now turning Food52’s culinary family of brands (including Schoolhouse and Dansk) into a cutting-edge content and commerce machine. She is the author of “Nobody Cares About Your Career: Why Failure Is Good, the Great Ones Play Hurt, and Other Hard Truths.”

• Ida Tin, Co-Founder and former CEO of Clue and Director of Femtech Assembly: The visionary who coined “femtech” in 2016 and built Clue into a global phenomenon with 12+ million users across 190+ countries.

• Althea Wishloff, General Partner at Raven Capital: A member of the Gitxsan Nation who leads the only venture fund dedicated to funding Indigenous and Native American entrepreneurs, overseeing a $110 million fund.

• Harley Finkelstein, President of Shopify: Canadian entrepreneur and former CBC Next Gen Dragon, recognized for his leadership and prestigious accolades: Canadian Angel Investor of the Year, Canada’s Top 40 Under 40, and Fortune’s 40 Under 40 awards.

• Hussein Fazal, Co-Founder and CEO of Super.com: Repeat tech entrepreneur who drove $1B in sales on Super.com. His previous accolades include bootstrapping AdParlor to $100M, and receiving EY’s Entrepreneur of the Year recognition.

Additional speakers to be announced.

We’re living through one of the most transformative periods in tech history,” commented Lisa Zarzeczny, Co-Founder & CEO of Elevate. “It’s an honour to welcome leaders who are not just navigating this change, but shaping the future at its very edge.”

Enhanced Programming and Multi-Dimensional Experience
New this year, Elevate’s most popular content tracks, AI and Scale Up, are moving to the Main Stage, enabling over 2,000 people to join each session. The Festival’s eight content tracks address topics most critical to Canada’s innovators: AI, Moonshots, Fintech, Shop Talk, Future Focus, Scale Up, plus specialized programming for investors and Women+ in tech.

Elevate Festival offers multiple specialized experiences all under one roof:

• Gender Parity in Action: The Women in Tech Lounge, presented by Interac, welcomes women+ and invites allies to listen, learn, and take action. It’s a space to show support and become true champions for gender equity in tech.

• Founder Acceleration Hub: The Startup Lounge, presented by Moneris, functions as a compressed accelerator experience, combining 1-1 investor meetings, expert advisory sessions, and high-stakes pitching.

• Deal-Making Infrastructure for Investors: Purpose-built spaces facilitate startup connections, with dealflow sessions that have historically generated funding conversations and commitments.

• Skills-First Learning: Back by popular demand, Masterclasses cap enrollment at 100 to ensure hands-on application, covering immediately implementable strategies from AI deployment to capital acquisition.

• Strategic VIP Networking: The limited-number of premium Trailblazer Passes creates a premium tier where executives forge industry-reshaping partnerships, with dedicated lounges and speaker access.

Beyond the Festival, Elevate runs year-round innovation programs like the eCommerce North Accelerator, made possible thanks to Moneris. These initiatives are woven into the Elevate Festival experience to offer deeper, ongoing support for startups.

Tickets are available now with Early Bird Sale pricing until June 30th. For more information, visit www.ElevateFestival.ca.

Elevate Festival is made possible by its Founding Sponsors: Interac, Moneris and TD Bank Group, as well as its Corporate Sponsors: Google, the Government of Ontario, the City of Toronto, DMZ, Capital One, KPMG, Danone, CPA Ontario, Riipen, OddBee, Bizzabo, Divine Furniture Rental, Get Wrapped, Interprefy, AccessWire and Fintechs Canada, and Official Media Partner: Globe and Mail.

About Elevate
Elevate is a Canadian non-profit that unites world-class innovators to catalyze transformation in the Canadian tech ecosystem. Through year-round programs and events, including the annual Elevate Festival and CIX Summit, Elevate shines a spotlight on Canadian innovation, facilitates global connections with startups and investors, and inspires Canadians to embrace a go-for-gold mentality to help shape the future of the Canadian innovation economy.

—

Media Details:

• Access the Elevate Festival promo video at https://www.youtube.com/watch?v=4mBHZ8K9ysE.

• Photo caption: Kara Swisher and Lisa LaFlamme on stage at Elevate Festival 2024. Photo courtesy of Elevate Festival

• Media can apply for accreditation at Elevatefestival.ca/press-room/. Join the conversation by following @ElevateTechCA and #ElevateFest2025.

Media Contact:
Amanda Connon-Unda
Senior Director of Marketing, Elevate
amanda@elevate.ca

SOURCE: Elevate

View the original press release on ACCESS Newswire

TORONTO, ONTARIO / ACCESS Newswire / May 27, 2025 / Electrovaya Inc. (Nasdaq:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, today announced that it will host an investor webcast presentation on June 3, 2025 at 2:00 PM EDT.

During the webcast, Dr. Raj DasGupta., CEO and John Gibson, CFO, will conduct an introductory presentation that will cover key aspects of Electrovaya’s business including corporate strategy, business model, and industry-leading technology. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

https://us02web.zoom.us/webinar/register/WN_QU4ncWdfRaWS5hVR_-ptkg

Investor and Media Contact:

Jason Roy
VP, Corporate Development and Investor Relations
Electrovaya Inc.
jroy@electrovaya.com / 905-855-4618

About Electrovaya Inc.

Electrovaya Inc. (NASDAQ:ELVA) (TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries. The Company has extensive IP and designs, develops and manufactures proprietary lithium-ion batteries and battery systems for energy storage and heavy duty electric vehicles based on its Infinity Battery Technology Platform. This technology offers enhanced safety and industry leading battery longevity. The Company is also developing next generation solid state battery technology at its Labs division. Headquartered in Ontario, Canada, Electrovaya has two operating sites in Canada and has acquired a 52-acre site with a 135,000 square foot manufacturing facility in New York state for its planned gigafactory. To learn more about Electrovaya, please explore www.electrovaya.com.

SOURCE: Electrovaya, Inc.

View the original press release on ACCESS Newswire

Ambience’s latest AI model reduces coding errors and targets $266 billion in annual administrative waste

SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2025 / Ambience Healthcare today announced a major advancement in ambient AI, unveiling the first AI model that outperforms board-certified physicians in ICD-10 coding accuracy.

Trained using OpenAI’s Reinforcement Fine-Tuning (RFT) technology, Ambience’s AI platform achieved a 27% relative improvement over physician benchmarks-reducing coding errors by approximately one-quarter and offering a powerful tool to tackle the $266 billion in annual administrative waste, including $19 billion in diagnosis coding & documentation substantiation errors.

This new model identifies precise ICD-10 codes based on patient encounters, which feed into Ambience’s ‘coding-aware’ scribe. By leveraging these codes first, the scribe generates a fully informed note-allowing clinicians to review and confirm accurate documentation and coding in real time.

“Think of this technology as a scribe that fluently speaks both clinical language and the intricate healthcare billing rulebook from day one,” said William H. Morris, MD, MBA, Chief Medical Officer of Ambience Healthcare. “Our platform helps clinicians finish their notes faster and ensures that revenue cycle teams receive cleaner, more accurate, and audit-ready charts.”

Ambience is live across inpatient, outpatient, and emergency settings at health systems throughout the United States, supporting over 100 medical specialties with real-time, compliant documentation. Clinicians at more than 40 organizations including UCSF Health, St. Luke’s Health System, Houston Methodist, John Muir Health, and Memorial Hermann Health System leverage Ambience before, during, and after patient encounters to generate compliant documentation, alleviate burnout, and enhance care quality.

How Ambience’s “Coding-Aware” AI Scribe Works
Ambience Healthcare’s platform streamlines the clinical documentation and coding process:

• Clinicians simply tap ‘Record’ on their device, conduct patient visits as usual, and then review a draft note, complete with suggested ICD-10 and CPT codes;

• Ambience integrates natively with major EHRs-including Epic, Oracle Cerner, and athenahealth-ensuring that after clinicians review and sign off, the complete and coded documentation is automatically filed back into the patient’s record;

• By addressing coding at the point of care, Ambience eliminates downstream compliance issues and the time-consuming back-and-forth queries between clinicians and coding/billing departments.

“We built for compliance at the core of our platform because health systems need assurance that AI technology in the workflow can stand up to audits, protect reimbursement, and support clinical documentation integrity,” said Michael Ng, CEO and Co-Founder of Ambience Healthcare. “The stakes of getting this wrong are too high for compliance to be an afterthought.”

Validated Results with RFT Technology
To validate its AI’s mastery of the “coding rulebook,” Ambience assembled a “gold-panel” test dataset of complex clinical cases spanning multiple medical specialties. Each encounter was meticulously labeled by a consensus of four or more expert clinicians to establish a high-quality ground truth.

“Reinforcement Fine-Tuning lets developers align powerful AI models with the precision and robustness that high-stakes domains like healthcare demand,” said Shyamal Anadkat, Head of Startup Solutions at OpenAI. “Ambience’s results show how RFT can lift the performance of AI systems in safety-critical environments”.

The Ambience model was benchmarked against 18 experienced, board-certified physicians on ICD-10 coding accuracy. The results were significant: Ambience’s AI demonstrated a 27% relative improvement in coding performance compared to the expert physician baseline, suggesting the model could help eliminate up to one quarter of the coding errors even the most seasoned clinicians make.

About Ambience Healthcare
Ambience Healthcare is the leading AI platform for clinical documentation, CDI, and coding-built to ensure compliance, eliminate administrative burden, and improve care delivery. Trusted by top health systems across North America, Ambience’s platform is live across outpatient, emergency, and inpatient settings, supporting more than 100 specialties with real-time, coding-aware documentation. The platform integrates directly with Epic, Oracle Cerner, athenahealth, and other major EHRs. Founded in 2020 by Mike Ng and Nikhil Buduma, Ambience is headquartered in San Francisco and backed by Andreessen Horowitz, OpenAI Startup Fund, Kleiner Perkins, and other leading investors.

Media Contact
Karina Stabile
Aria Marketing for Ambience Healthcare
kstabile@ariamarketing.com
516-317-5835

SOURCE: Ambience

View the original press release on ACCESS Newswire

AI-Native Analytics Platform That Understands Your Business – and Your Developers

SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2025 / GoodData today announced the general availability of GoodData AI, a next-generation analytics platform that places AI at every layer of the data stack – from raw-data ingestion to governed insight delivery – without compromising trust or compliance.

Why GoodData AI Stands Apart

GoodData AI is designed for enterprises that require trust, scalability, and extensibility. Its architecture is built around these foundational principles:

• Composable by design: Embedded, white-labeled, and API-first; built for developers to connect with any AI stack.

• Semantic layer and ontology: The only AI analytics engine that natively understands your business logic, ensuring every answer is both consistent and metric-perfect.

• Model Context Protocol (MCP) Support: Enables real-time, cross-system context that makes AI relevant. GoodData’s new MCP Server Beta program is now available!

• AI you can trust: No data ever leaves your environment; every insight is explainable, auditable, and private by default.

• Analytics as Code: Turns GenAI from an opaque magic box into a governed, testable, and repeatable artifact within the analytics release cycle.

Roman Stanek, Founder & CEO of GoodData, said:

“Most generative AI pilots stall because they rely on ungoverned data. GoodData AI combines an open Analytics Lake, an Intelligent Semantic Layer, and AI Anywhere into one unified product. Our customers receive reliable insights instantly – directly in their apps and workflows – without needing any re-architecture.”

Core GoodData AI Capabilities

• AI Anywhere: Supports natural language interactions across various interfaces – within GoodData UI or embedded in your applications, with full white-label options available.

• Intelligent Semantic Layer: Uses domain ontologies and semantic models to ensure AI understands and speaks the language of your business.

• Natural Language Insights: Offers conversational data interactions, generating accurate answers, visualizations, and actionable suggestions.

• AI-Ready Analytics Lake: Ensures high-quality, unified data, facilitating scalable AI operations.

• Developer Tools and APIs: Provides flexible, API-first architecture for integration and automation within enterprise apps.

What Customers & Partners Are Saying About GoodData AI

“The intelligent semantic layer in GoodData gives us confidence. We know the data behind every AI-generated insight is consistent, reliable, and ready for action.”

Wagner Nascimento Filho, Development Manager for Analytics & IAM at TOTVS

“We’re thrilled to partner with GoodData to bring the power of white-labeled AI-driven analytics directly to our customers. GoodData’s natural language capabilities will allow our customers to interact with their data conversationally, making it easier than ever for our customers to generate insights and visualize results rapidly.”

Manoj Kumar, CTO at Atheer

“GoodData AI makes complex data easy to understand without requiring deep technical knowledge, which aligns perfectly with our mission at Salted CX. With GoodData AI’s context-aware metadata and Salted CX’s content analysis, we’re able to provide our customers with deeper analytics and understanding of conversations with their agents and bots.”

Simon Vostry, Co-Founder & CEO at Salted CX

Availability & Pricing

GoodData AI is available today on AWS, Azure, GCP, and private-cloud Kubernetes. Pricing starts with a Community tier (three users, one model route), scaling to Enterprise and OEM plans that bundle lake-compute credits and LLM token packs.

Looking Ahead

GoodData AI marks the beginning of a new era of BI, where AI isn’t just a bolt-on assistant but a core, intelligent layer within the analytics stack. As the platform evolves, expect deeper orchestration and integration, and more intuitive user experiences, delivered at scale, securely, and in full alignment with enterprise needs.

AI will continue to expand across every layer of the GoodData platform, powering intelligence everywhere it’s needed.

About GoodData

GoodData is the AI-native analytics platform built for speed, scale, and trust, helping companies deliver real-time insights – embedded, branded, and everywhere your users need them.

Founded in 2007, and with offices in both the U.S. and Europe, GoodData serves over 140,000 of the world’s top companies and 3.2 million users, helping them drive meaningful change and maximize the value of their data.

For more information, visit GoodData’s website and follow GoodData on LinkedIn, YouTube, and Medium.

GoodData Contact

press@gooddata.com

©2025, GoodData Corporation. All rights reserved. GoodData and the GoodData logo are registered trademarks of GoodData Corporation in the United States and other jurisdictions. Other names used herein may be trademarks of their respective owners.

SOURCE: GoodData

View the original press release on ACCESS Newswire

AUSTIN, TX / ACCESS Newswire / May 27, 2025 / Volcon ePowersports (NASDAQ:VLCN) (“Volcon” or the “Company”)) the first all-electric, off-road powersports company, received its first purchase order from Advanced EV for 1,000 golf carts.

This initial order will be used by Volcon to conduct market testing of a new golf cart model developed in conjunction with Super Sonic under the distribution agreement with Volcon previously announced in February 2025. The order represents a first step in exploring a broader relationship between the two companies.

“We’re excited to supply Advanced EV with this test order and see it as a strong foundation for future collaboration,” said John Kim, CEO, Volcon. “As an OEM manufacturing partner, we look forward to the opportunity to help bring innovative and high-quality products to Advanced EV’s dealer network and customer base.”

Birju Patel, CEO of Advanced EV, added, “We’re pleased to be working with Volcon on this initial test order. Their distribution capabilities and ability to move quickly make them a valuable partner as we explore new product offerings to serve our growing customer base.”

“This is the second multi-million dollar deal in the last five weeks,” said Josh Rasmussen, CSO of Volcon. “We’re excited to see the growth trajectory for Volcon and believe this momentum signals a strong future ahead.”

The Company also adds that it has resumed its share repurchase program.

About Volcon
Based in the Austin, Texas area, Volcon was founded as the first all-electric power sports company producing high-quality and sustainable electric vehicles for the outdoor community. Volcon electric vehicles are the future of off-roading, not only because of their environmental benefits but also because of their near-silent operation, which allows for a more immersive outdoor experience.

Volcon’s vehicle roadmap includes both motorcycles and UTVs. Its first product, the innovative Grunt, began shipping to customers in late 2021 and combines a fat-tired physique with high-torque electric power and a near-silent drive train. The Volcon Grunt EVO, an evolution of the original Grunt with a belt drive, an improved suspension, and seat, began shipping to customers in October 2023. The Brat is Volcon’s first foray into the wildly popular eBike market for both on-road and off-road riding and is currently being delivered to dealers across North America. In 2024, Volcon entered the rapidly expanding LUV and UTV market and shipped its first production MN1 unit in October 2024. The new MN1 and HF1 products empower the driver to explore the outdoors in a new and unique way that gas-powered units cannot. They offer the same thrilling performance of a standard LUV / UTV without the noise (or pollution), allowing the driver to explore the outdoors with all their senses.

Volcon Contacts
For Media: media@volcon.com
For Dealers: dealers@volcon.com
For Investors: investors@volcon.com
For Marketing: marketing@volcon.com

For more information on Volcon or to learn more about its complete eBike, motorcycle and side-by-side line-up, visit: www.volcon.com

Forward-Looking Statements
Some of the statements in this release referenced in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, whether the full purchase order will be fulfilled and when the units will be delivered and when share repurchases will be completed. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC’s website, www.sec.gov.

SOURCE: Volcon, Inc.

View the original press release on ACCESS Newswire

Support for Bitcoin and Stablecoins on Lightning Underscores ALT5’s Commitment to Scalable, Real-Time Settlement Infrastructure

LAS VEGAS, NEVADA / ACCESS Newswire / May 27, 2025 / ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ:ALTS)(FRA:5AR1), a fintech company that delivers blockchain-powered payment and trading infrastructure for global merchants and financial institutions, today announced that Lightning Network capabilities are now live on its platform.

This upgrade enables instant, low-cost Bitcoin payments on ALT5 and lays the foundation for Tether (USDT) stablecoin support over Lightning, delivering a powerful combination of speed, stability, and cost-efficiency for enterprises that depend on high-frequency digital transactions.

ALT5’s Lightning integration is made possible through Voltage, a leading provider of enterprise-grade Lightning infrastructure. By embedding Lightning into its Crypto-as-a-Service ecosystem, ALT5 enables clients to benefit from real-time settlement, whether transacting in Bitcoin or increasingly in stablecoins such as USDT.

“Real-time payments are no longer optional-they’re becoming essential for modern finance,” said Peter Tassiopoulos, CEO of ALT5 Sigma. “With Lightning now available on our platform, we’re giving institutions a direct path to instant Bitcoin payments and preparing for the growing demand for stablecoin settlement over Lightning.”

The introduction of Lightning on ALT5 unlocks a new class of use cases for digital asset settlement, particularly in cross-border commerce, high-frequency trading, and global merchant payments. Clients can now dramatically reduce fees and confirmation times, while maintaining the robust compliance and operational controls built into ALT5’s infrastructure.

“The ability to move Tether over Lightning is an inflection point for the industry,” said Graham Krizek, CEO of Voltage. “It’s a stable, scalable payment method layered on top of Bitcoin’s security and ALT5 is making that future accessible to institutions today.”

The evolving potential for stablecoin settlement over Lightning presents new opportunities for financial platforms. ALT5 is closely monitoring this space as part of its ongoing commitment to delivering scalable, future-ready payment infrastructure for global enterprises.

With Lightning now integrated, ALT5’s platform supports a full range of crypto transaction protocols, enabling real-time settlement across Bitcoin, stablecoins, and multiple networks. Regardless of the asset or underlying technology, transactions can now be initiated, routed, and settled through ALT5’s unified infrastructure.

For more information on ALT5 Sigma’s payment solutions and its integration with Voltage, visit http://alt5sigma.com/.

About ALT5 Sigma

ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) is a fintech company, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment and safe keeping of digital assets. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024.

Founded in 2018, ALT5 Sigma, Inc. (a wholly owned subsidiary of ALT5 Sigma Corporation), provides next-generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Sigma has processed over $5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

The Company is working on the separation of our biotech business that will move forward under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

About Voltage

Voltage is a leading enterprise Lightning Network provider, offering scalable infrastructure for businesses looking to integrate instant, low-cost Bitcoin payments. With a mission to drive mainstream Lightning adoption, Voltage provides businesses with the tools they need to leverage Bitcoin’s fastest and most efficient payment layer.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5’s platforms and business that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion. This press release also may contain statements or links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company’s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media Contact

Media/Investor Relations
ALT5 Sigma Corporation
ir@alt5sigma.com
1-800-400-2247

SOURCE: ALT5 Sigma Corp.

View the original press release on ACCESS Newswire

SYDNEY, AU / ACCESS Newswire / May 27, 2025 / Dateline Resources Limited (ASX:DTR)(OTC PINK:DTREF), a leading Australian exploration company advancing high-potential mineral projects in North America, is thrilled to announce promising exploration results from its 100%-owned Colosseum Rare Earth Element (REE) and Gold Project in California’s mineral-rich Walker Lane Trend, East San Bernardino County. As of May 21, 2025, recent field mapping and geochemical sampling have revealed a significantly expanded mineralized system, with the potential to unlock substantial REE opportunities and grow the project’s 1.1-million-ounce gold resource, positioning Colosseum as a cornerstone asset for Dateline.

Groundbreaking Exploration Discoveries

Recent exploration efforts have focused on felsite (rhyolite) outcrops located 200-900 meters west and southwest of the Colosseum open pits, mined in the late 1980s and early 1990s. These findings provide tangible evidence of a broader intrusion-related mineral system that could host significant REE deposits and additional gold zones beyond the historically worked areas.

Key Exploration Highlights:

• Strategic REE Potential: Located less than 10 km from the Mountain Pass Rare Earth mine, Colosseum’s mantle-derived rocks and carbonatite associations suggest a promising REE initiative. The presence of pathfinder elements and geological similarities to nearby REE deposits indicate potential for millions of tons of critical minerals like neodymium and dysprosium, essential for clean energy, electronics, and defense technologies.

• Expanded Mineralized Footprint: Geochemical anomalies in felsite samples, including elevated levels of antimony (Sb), bismuth (Bi), tellurium (Te), arsenic (As), and traces of silver (Ag), indicate a distal halo typical of intrusion-related gold systems (IRGS), where gold and potentially REEs are concentrated in central zones at depth or along strike.

• New Felsite Outcrops: Newly identified felsite dykes align with the structural trends of the known breccia pipes, following an orthogonal fracture system and ring-dyke pattern associated with an underlying intrusive body. These dykes, observed in a semi-circular pattern around the pits, are satellites to the main felsite intrusion, potentially feeding additional REE- and gold-bearing structures.

• Untapped Potential: Historical exploration was limited to 641 drill holes targeting two breccia pipes within or near the pits, leaving vast areas of the claims untested. No comprehensive property-wide geochemical survey was previously conducted, highlighting significant opportunities for new REE and gold discoveries.

• Exploration Targets: Priority zones include breccia pipe extensions and felsite-hosted mineralization along the established structural trends, with a maiden drill program planned to test for both REE and gold potential.

Current Resource and Geological Model

The Colosseum Project is strategically positioned to capitalize on its REE potential, complemented by a robust gold resource. The gold component hosts a JORC-2012 compliant Mineral Resource estimate, announced on June 6, 2024, totaling 27.1 million tonnes at 1.26 grams per tonne (g/t) gold, equating to 1.1 million ounces, categorized as:

• Measured: 455,000 ounces at 1.47 g/t (41%, highest confidence).

• Indicated: 281,000 ounces at 1.21 g/t (26%, moderate confidence).

• Inferred: 364,000 ounces at 1.10 g/t (33%, preliminary estimate).

Geological mapping confirms that the newly discovered felsite dykes align with the deposit’s structural framework, characterized by a pronounced orthogonal fracture system and a ring-dyke pattern tied to an underlying intrusive body. Surface mapping prior to open-pit mining illustrates a semi-circular pattern of felsite (rhyolite) breccia outcrops surrounding the Colosseum pits, consistent with the historic geological model (Source: Geology Notes, 1983). The felsite outcrops, located 200-900 meters west and southwest of the north and south pits, align with the modeled subsurface felsite body, indicating potential extensions of breccia pipes hosting both REEs and gold (see Figures 1-3 in the original exploration report).

Geochemical and Alteration Insights

Detailed geochemical analysis of the felsite samples provides critical insights into the mineralizing system, supporting both REE and gold potential:

• Magma Evolution: The felsite is indicative of a highly fractionated, moderately oxidized granitic melt. Abundant zircon (zirconium-rich minerals) and early magnetite crystallization suggest extensive fractional crystallization, concentrating incompatible elements like bismuth (Bi) and tellurium (Te), typical of IRGS deposits and often associated with REE-enriched systems.

• Alteration Patterns: Intense potassic alteration (secondary K-feldspar and biotite) and phyllic alteration (sericite-quartz-pyrite overprint) confirm significant hydrothermal fluid activity, a key driver of both REE and gold deposition. A ~2-meter-wide felsite dyke oriented southwest exhibits alteration patterns consistent with the mineralized breccia pipes (see Figure 4 in the original exploration report).

• Pathfinder Elements: Elevated levels of Bi, Te, Sb, As, and traces of Ag, often associated with bismuth-telluride minerals in gold deposits, also align with REE-bearing systems. These elements form a distal geochemical halo, suggesting that the surface exposures lie peripheral to a mineral-rich core potentially containing both REEs and gold.

The geochemical and alteration profile matches the outer zone of an intrusion-related mineral system, adding credence to the possibility of a large, zoned system at Colosseum with significant REE and gold potential.

Mineral Potential and Quantities

Confirmed Minerals (June 6, 2024 Resource Estimate):

• Gold (Au): 1.1 million ounces from 27.1 million tons at 1.26 g/t.

  • Measured: 455,000 oz at 1.47 g/t.

  • Indicated: 281,000 oz at 1.21 g/t.

  • Inferred: 364,000 oz at 1.10 g/t.

• Pathfinder Elements: Trace amounts of antimony (Sb), bismuth (Bi), tellurium (Te), arsenic (As), and silver (Ag) in felsite samples, indicating a fertile mineral system.

Additional Minerals:

• REEs: Proximity to the Mountain Pass mine and the presence of mantle-derived rocks and carbonatite associations suggest potential for millions of tons of REEs, such as neodymium or dysprosium, pending further exploration.

• Gold: Breccia pipe extensions or deeper felsite-hosted zones could add hundreds of thousands of ounces, pending drilling confirmation.

• Pathfinder Elements: Sb, Bi, Te, As, and Ag may be economically viable as byproducts in IRGS deposits if gold and REE grades are high.

Historical Context and Untapped Opportunities

Historical exploration at Colosseum was narrowly focused, with all 641 drill holes targeting the two main breccia pipes within or near the open pits for gold. No drilling or comprehensive geochemical surveys were conducted outside these areas, and REE potential was not systematically explored. The recent discovery of pathfinder anomalies in felsite outcrops, enriched in Bi, Te, Sb, and As, represents evidence of mineralization beyond the mined zones, highlighting the potential for significant new REE and gold discoveries.

Strategic Exploration Roadmap

Dateline is advancing a robust exploration program to capitalize on the REE and gold potential:

• REE Investigation: Quantifying REE potential in mantle-derived rocks and carbonatites, leveraging proximity to the Mountain Pass Rare Earth mine.

• Expanded Geochemical Sampling: Extending surface sampling along the projected trend of the felsite dykes to delineate the mineralized corridor for both REEs and gold.

• Maiden Drill Program: Targeting breccia pipe extensions at depth beneath the newly identified felsite outcrops and adjacent structural zones mirroring the ring-dyke pattern to test for REE and gold deposits.

• Geophysical Surveys: Evaluating geophysical technology to refine drill targets and further map subsurface extensions of the felsite intrusion for REE and gold potential.

Managing Director Stephen Baghdadi stated, “The Colosseum Project is poised for transformative growth. These findings confirm a larger mineral system, with the potential to significantly expand our 1.1-million-ounce gold resource and establish Colosseum as a key REE player. We are committed to aggressively moving the project forward and delivering exceptional value to our stakeholders.”

Economic Outlook

On May 23, 2025, Dateline announced updated economics for the Colosseum Gold Project, generating an NPV6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz. The emerging REE potential and expanded mineralized footprint further enhance the project’s economic viability, positioning it as a strategic asset for critical minerals and precious metals.

About Dateline Resources Limited

Dateline Resources Limited (ASX: DTR) is an Australian publicly listed company focused on high-value mining and exploration in North America. The Colosseum REE and Gold Project, located in California’s Walker Lane Trend, is a flagship asset with emerging REE potential and proven gold resources.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable securities laws. These statements relate to future events or future performance and include, but are not limited to, statements regarding the potential of the Colosseum Project, the expected benefits of the OTCQB listing, the company’s plans for future development, and the strategic importance of the project for U.S. critical minerals supply. Forward-looking statements are based on the company’s current expectations, estimates, and projections, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to: fluctuations in the prices of gold and rare earth elements; changes in regulatory requirements or permitting processes; geological or technical challenges in exploration and development; market conditions affecting the company’s ability to raise capital; environmental or social factors impacting operations; risks associated with the OTCQB listing process or trading on a new market; environmental and permitting risks associated with operating in a national preserve; uncertainty regarding the delineation of a mineable rare earth elements resource; risks related to the company’s ability to secure necessary funding for project development; and potential changes in government policies or priorities affecting the critical minerals sector. The company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company does not undertake any obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Competent Person Statement

The exploration data has been reviewed by Mr. Greg Hall, a Chartered Professional of the Australasian Institute of Mining and Metallurgy (CP-IMM) and Non-Executive Director of Dateline. Mr. Hall, with extensive experience in IRGS-style mineralization, qualifies as a Competent Person under the JORC Code and consents to the inclusion of this information.

Contact Information

For further details, please contact:

• Stephen Baghdadi, Managing Director, +61 2 9375 2353, www.datelineresources.com.au

• Andrew Rowell, White Noise Communications, +61 400 466 226, andrew@whitenoisecomms.com

Follow Dateline on X: @Dateline_DTR

This announcement is authorized for release by the Dateline Resources Limited Board of Directors.

SOURCE: Dateline Resources Limited

View the original press release on ACCESS Newswire